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Commentary
The spread of pathogenic bacteria that are resistant to 
certain antibiotics constitutes a growing threat to public 
health. One strategy to counter this problem is to 
minimize the probability that antibiotic resistance arises. 
To achieve this we need to understand the factors that 
drive and constrain its evolution [1]. The fitness costs 
associated with resistance have received considerable 
attention since they determine the long-term success of 
resistant bacteria. Such costs may arise from modifi-
cations of cellular components with vital functions, such 
as ribosomes or the cell wall, or from metabolic costs due 
to the expression of enzymes that break down the anti-
biotic. These pleiotropic costs would allow resis tance to 
be selected only when bacteria are confronted with anti-
biotics. Surprisingly, a study published in BMC Evolu­
tionary Biology [2] now reports the fixation of mutations 
causing rifampicin resistance in Escherichia coli popula-
tions that evolved at high temperature in medium with-
out any antibiotics. By gauging the fitness consequences 
of these mutations in other environments and in other 
bacterial strains, the authors show that the beneficial 
effects of these mutations are highly specific and 
highlight two factors that are crucial for the evolution of 
antibiotic resistance: pleiotropy and epistasis.
The study by Rodríguez-Verdugo et al. [2] analyses 
E.  coli lines from a previously reported large-scale 
evolution experiment with 114 populations that have 
evolved for 2,000 generations at an increased temperature 
of 42.2°C [3]. Genome sequencing of clones from all 
evolved populations showed that 74 clones contained at 
least one of 46 unique non-synonymous mutations in the 
rpoB gene [3], which encodes the β-subunit of RNA 
polymerase and is a known target of rifampicin resistance 
[4]. Thirteen of the 114 lines did acquire intermediate to 
very high levels of rifampicin resistance. Interestingly, all 
13 resistant lines had a non-synonymous mutation in 
rpoB, and 12 showed one of three mutations at codon 
position 572, thus showing signatures of parallel 
evolution - a hallmark of their involvement in adaptation. 
By looking at the temporal dynamics the researchers 
showed that these mutations appeared early in the selec-
tion, again consistent with their involvement in adapta-
tion. The authors obtained definitive proof that the three 
mutations at position 572 increase fitness in the evolu-
tionary environment by testing their effect in the ances-
tral strain, revealing fitness increases of about 20%.
How surprising are these results? Resistance mecha-
nisms are generally thought to be costly since antibiotics 
target fundamental cellular processes, including the 
synthesis of mRNA, proteins and cell structures [4]. 
Fitness costs associated with resistance may arise from 
modifications in the cellular targets of antibiotics, which 
prevent binding of the drug but also compromise their 
cellular role. This is, for instance, the case for resistance 
to rifampicin and streptomycin, which target the β-
subunit of RNA polymerase and ribosomal protein S12, 
respectively. Costs may also be due to the synthesis of 
enzymes that break down antibiotics, as is the case for β-
lactams, or when porin mutations that interfere with the 
antibiotic entering the cell also limit the uptake of 
nutrients, as for penicillin and tetracycline. Many studies 
have quantified such costs in the absence of the antibiotic 
under various in vitro and in vivo conditions [4]. But a 
‘cost of resistance’ was not always observed, and neutral 
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or even beneficial effects in the absence of the drug have 
previously been observed for resistance to a number of 
other antibiotics (reviewed in [4]). Complementary to the 
results of Rodríguez-Verdugo et al., a recent study 
showed that E. coli selected in the presence of rifampicin 
acquired mutations in the rpoB gene that were beneficial 
in minimal medium at increased temperature [5]. 
However, other than the study by Rodríguez-Verdugo et 
al., these studies lacked genomic information and could 
not rule out the possibility that secondary mutations 
have occurred that compensated for the negative 
pleiotropic effects of the resistance mutations.
Pleiotropy and epistasis
Rodríguez-Verdugo et al. further tested the effect of the 
rpoB mutations in other bacterial strains, in other growth 
media and at other temperatures (in the absence of 
rifampicin), and found that the benefits are specific for 
the environmental conditions and genetic background 
used. Their study thus illustrates the crucial role of pleio-
tropy and epistasis as factors that constrain the evolution 
of antibiotic resistance. Pleiotropy occurs when a single 
mutation affects multiple phenotypic traits, and epistasis 
when mutations at different loci interact in non-additive 
ways in their effect on a phenotype or on fitness. These 
features reflect the genetic wiring connecting genotypes 
and phenotypes (Figure  1a), and can be considered 
fundamental properties of biological systems. Evolution-
ary constraints from pleiotropy arise when mutations 
have positive effects on one phenotype and negative 
effects on another, thereby making adaptation specific for 
conditions requiring the first phenotype. An additional 
constraint from negative or antagonistic pleiotropy is its 
effect on the number and fitness effects of beneficial 
mutations, and the associated probability that the same 
mutation will be repeatedly selected under the given 
conditions [6]. The chance that two independently 
evolving populations adapt by selecting the same bene-
ficial mutation becomes relatively high when mutations 
are present with an exceptional benefit - as was recently 
found for the resistance to cefotaxime caused by muta-
tions in TEM-1 β-lactamase [7].
Epistasis, the non-additive interaction of mutations at 
multiple loci, plays a major role when resistance to 
antibiotics requires the sequential substitution of mul-
tiple mutations. Sign epistasis - which occurs when 
muta tions are beneficial in one background and deleter-
ious in other backgrounds - introduces particularly 
strong constraints. It reduces the number of mutational 
pathways leading from sensitive to highly resistant 
mutants that are accessible to natural selection [8], 
thereby making evolution more predictable. Mutational 
Figure 1. Pleiotropy and epistasis are key factors in the evolution of antibiotic resistance. (a) Definition of pleiotropy and epistasis. 
Phenotypes P1 and P2 affect fitness (or antibiotic resistance) and are determined by genes a and b. Plus/minus signs indicate positive/negative 
effects. Gene a has antagonistic pleiotropic effects on both phenotypes, while gene b is not pleiotropic. Epistasis is the dependence of the 
phenotypic or fitness effect of a gene on the effect of another gene; epistasis at the level of fitness may thus arise from gene interactions 
determining underlying phenotypes or from interactions among phenotypes in their effect on fitness, or both (opportunity for epistasis indicated 
by double-headed red arrows). (b) Knowledge of pleiotropy and epistasis allows evolutionary predictions. Shown are fitness effects of alleles A and 
B in a red and in a blue environment. In both environments, AB is the fittest (or most resistant) combination. In the red environment, A and B are not 
epistatic and both pathways from ab to AB (shown by red arrows) are equally likely. However, in the blue environment, alleles A and B show sign 
epistasis, leading to the low-fitness combination Ab. As a result, one pathway (ab > aB > AB, shown by blue arrows) is much more likely under the 
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pathways can be visualized on fitness landscapes, where 
fitness is mapped onto genotypes carrying all possible 
combinations of a set of mutations that contribute to 
adaptation. In theory, with full knowledge of the fitness 
landscape one should be able to predict the most likely 
path leading to full antibiotic resistance under any given 
condition; such predictions may be extended to other 
conditions with knowledge of the pleiotropic effects of 
the mutations (Figure 1b). Even for a single condition, full 
knowledge of the fitness landscape is, however, un-
realistic, because the number of combinations grows 
exponentially with the number of contributing mutations. 
Current attempts to study empirical fitness landscapes by 
systematically analysing mutants carrying all possible 
combinations of sets of interesting mutations [9] are 
there fore necessarily restricted to sets of a handful of 
mutations. A complicating factor is that the predictability 
of evolution not only depends on knowledge of the fitness 
landscape, but also on population dynamic variables, 
such as population size and mutation rate, which 
determine which of the possible pathways will actually be 
followed [10].
The prospect of predicting the evolution of antibiotic 
resistance may seem utopic, but it is gaining momentum. 
One stimulus is the growing number of observations of 
the repeated fixation of the same small set of resistance 
mutations in independently evolving populations [9], to 
which the study of Rodríguez-Verdigo et al. [2] can now 
be added. A growing number of evolutionary biologists 
use antibiotic resistance as an experimental system. The 
information on the molecular changes involved in anti-
biotic resistance that will result from these endeavors will 
feed models of evolution that can incorporate observed 
patterns of pleiotropy and epistasis and explore the con-
se quences under various population dynamic scenarios. 
With the aid of such models, we can start predicting what 
will happen when we expose pathogens to antibiotics, 
raising the prospect of devising strategies to reduce the 
probability that antibiotic resistance will arise. However, 
let us not be too optimistic: while we may be able to 
predict what happens when an antibiotic is present under 
controlled conditions in the laboratory, it will be even 
more challenging to predict how resistance develops 
under conditions that are unpredictable themselves.
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